Clinical trial · no report yet · Phase 1/Phase 2
NCT06026657
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
- NCT06026657 ↗
- Recruiting
- Margaret Gatti-Mays
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Phase 1b/2 Study of Naxitamab (Danyelza), Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells in Advanced GD2-expressing Breast Cancers (DiG NKs)
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma
- Interventions
- Biospecimen Collection; Computed Tomography; Gemcitabine; Magnetic Resonance Imaging; Naxitamab; Universal Donor Expanded TGF-beta-imprinted NK Cells
- Arms
- Arm I (Gemcitabine, TGFBi) · Experimental
- Arm II (Gemcitabine, TGFBi x2) · Experimental
- Arm III (Gemcitabine naxitamab, TGFBi) · Experimental
- Arm IV (Gemcitabine, naxitamab, TGFBi x2) · Experimental
- Enrollment
- 42 (estimated)
- Primary outcomes
- Incidence of adverse events
- Objective response rate
- Sponsor
- Margaret Gatti-Mays
- Start
- Apr 2, 2024
- Primary completion
- Oct 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06026657 · updated Jul 23, 2026